What question did this study set out to answer?

To determine whether peripheral-blood progenitor cells combined with GM-CSF can prevent cumulative myelosuppression during repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

August 1, 1993Journal of Clinical Oncology

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

View Full Paper

Ask AI

Bookmark

Authors

ITI TeplerNational Institutes of Health SCS A CannistraBeth Israel Deaconess Medical Center EFEmil FreiDana-Farber Cancer Institute

Discussion

Member takes

Implication

Clinical trial demonstrates that reinfused peripheral-blood progenitor cells reduce severe myelotoxicity from high-dose chemotherapy in cancer outpatients, indicating improved treatment tolerability.

Key Points

To determine whether peripheral-blood progenitor cells combined with GM-CSF can prevent cumulative myelosuppression during repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Mobilized and harvested PBPCs via 6 consecutive days of leukapheresis following cyclophosphamide (4 g/m2) and GM-CSF in N=8 assessable outpatients.
Administered four outpatient cycles of carboplatin (600 mg/m2) and cyclophosphamide (600 mg/m2) with GM-CSF every 28 days, comparing cycle 1 (GM-CSF alone) to cycles 2 through 4 (GM-CSF plus day-3 PBPC reinfusion).
PBPC reinfusion in cycle 2 significantly shortened the median duration of severe thrombocytopenia (< 20,000/µL; 1 vs. 6.5 days, P = .016), time to platelet recovery > 50,000/µL (15 vs. 20.5 days, P = .020), and platelet transfusions (1.5 vs. 5, P = .016) compared to cycle 1.
Median duration of neutropenia (< 1,000/µL) decreased from 7 days in cycle 1 to 2.5 days in cycle 2 (P = .008), with dose-limiting hematologic toxicity eliminated across cycles 2 through 4 (0 of 19 cycles) versus 4 of 8 patients in cycle 1.
Five of eight patients completed all four planned cycles, whereas three discontinued early due to delayed thrombocytopenia (n = 2) or disease progression (n = 1).

Cite This Study

Tepler et al. (1993) studied this question.

synapsesocial.com/papers/6a8a86ea7f5a142c17c14c3c https://doi.org/10.1200/jco.1993.11.8.1583

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates that reinfused peripheral-blood progenitor cells reduce severe myelotoxicity from high-dose chemotherapy in cancer outpatients, indicating improved treatment tolerability.

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

Discussion

Member takes

Implication

Key Points

Cite This Study

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider